Skip to content

Clinical Trials

Clinical Trials

RESIN

featureImage
Read HCC paper here
featureImage
Read full mCRC paper here
featureImage
Read full safety paper here


Patients enrolled

Real-world data from RESiN support evidence on the efficacy and safety of SIRT with
SIR-Spheres® Y-90 resin microspheres2-4

Results from the mCRC cohort3,4



Patients enrolled


Abbreviations:
HCC: Hepatocellular carcinoma ; mCRC: metastatic colorectal cancer ; ECOG PS: Eastern Cooperative Oncology Group - Performance Status ; SBRT: Stereotactic Body Radiation Therapy ; PVE: Portal vein embolization ; BSA : Body surface area ; OS: Overall survival ; PFS: Progression-free survival ; BCLC: Barcelona clinic liver cancer ;

References:

  1. Sirtex Press Release Aug 2020. https://appliedradiationoncology.com/articles/sirtex-completes-u-s-resin-registry-enrollment. Last access: Aug 12th 2021. 2. Frantz S et al. J Vasc Interv Radiol 2021; 32: 845–852. 3. Brown D et al. J Gastrointest Oncol 2021; 12(2):639-657. 4. Emmons et al. Radiol 2022; doi: 10.1148/radiol.220387.

Caution: Federal (USA) law restricts this device to sale by or on the order of a physician. Indications for Use: SIR-Spheres Y-90 resin microspheres are indicated for the treatment of unresectable metastatic liver tumors from primary colorectal cancer with adjuvant intrahepatic artery chemotherapy (IHAC) of FUDR (Floxuridine). Side Effects: Common side effects are fever, transient decrease of hemoglobin, mild to moderate abnormality of liver function tests, abdominal pain, nausea, vomiting, and diarrhea. Potential serious effects due to exposure to high radiation include acute pancreatitis, radiation pneumonitis, acute gastritis, radiation hepatitis, and acute cholecystitis. Consult the Instructions for Use for a complete listing of indications, contraindications, side effects, warnings, and precautions.